{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"}]}],"title":"Pre-LD chemo"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14554.838","value":"5271.59"}]}],"title":"Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"100449.434","value":"99960.98"}]}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"180377.654","value":"46586.56"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86387.497","value":"16290.81"}]}],"title":"Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53549.080","value":"7249.38"}]}],"title":"Day 30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18645.673","value":"567.88"}]}],"title":"Day 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11118.975","value":"251.52"}]}],"title":"Day 90"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2414.251","value":"90.52"}]}],"title":"Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1346.240","value":"64.81"}]}],"title":"Day 270"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"626.792","value":"41.26"}]}],"title":"Day 365"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Quantitation of CAR T-cells in peripheral blood will be determined at specified timepoints by quantitative PCR assay, measured in copies/mcg genomic DNA.","dispersionType":"Standard Deviation","groups":[{"description":"Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m\\^2 and fludarabine 30mg/m\\^2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x10\\^6 cells. Maintenance lenalidomide, starting at 5mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.\n\nLenalidomide: Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression\n\nbb2121: Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\\^6 cells.\n\nCyclophosphamide: 300 mg/m\\^2/day for 3 consecutive days prior to the CAR T infusion\n\nFludarabine: 30 mg/m\\^2/day or 3 consecutive days prior to the CAR T infusion\n\nleukapheresis: Placement of central line catheter and leukapheresis","id":"OG000","title":"Lenalidomide and bb2121"}],"paramType":"MEDIAN","populationDescription":"Participants who received an infusion","reportingStatus":"POSTED","timeFrame":"pre-LD chemo, day 4, 7, 14, 21, 30, 60, 90, 180, 270, 365","title":"Exploratory Objective 2: Summary Statistics of CAR T-cell Expansion","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"CAR T-cells (copies/mcg DNA)"}